Milan Kvapil s.r.o.
- Address
- Lucni 1611, 263 01 Dobris, Czechia
Cardiovascular Disease Research
At Milan Kvapil s.r.o., investigators are evaluating novel agents aimed at reducing major adverse cardiovascular events and improving lipid profiles in patients with atherosclerotic disease.
- Reducing cardiovascular events with oral therapies
- Lowering lipoprotein(a) to prevent coronary complications
- Managing severe hypertriglyceridemia
The site’s focus on cardiovascular outcomes supports patients at high risk while advancing preventive cardiology.
Metabolic and Nutritional Disease Research
Researchers are testing new treatments to lower body weight and improve glucose control in adults with type 2 diabetes and overweight or obesity, while also targeting abnormal lipid metabolism.
- Body‑weight reduction strategies
- Glycemic management compared with standard care
- Impact on metabolic health markers
By integrating weight‑loss and diabetes endpoints, the clinic aims to provide comprehensive solutions for metabolic health.
Hormonal and Endocrine Disorder Studies
The department’s endocrine expertise drives investigations into hormonal regulation, focusing on conditions such as obesity and related metabolic disturbances.
- Hormone‑based therapies for weight management
- Effects on insulin sensitivity
- Safety and tolerability in endocrine patients
This work complements the site’s broader cardiovascular and metabolic programs, offering a holistic approach to endocrine disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Milan Kvapil s.r.o.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Effect of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a): A Randomized, Placebo-Controlled Study | Amgen Inc. | Phase III | Not Recruiting | May 2023 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Isis 678354 Sodium Salt | 2 | Unknown | 2023-05-17 | 2023-06-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.